TMCnet News
5EU HER2-Positive Breast Cancer Market Report 2014 - Drug Forecast and Market Analysis to 2023(M2 PressWIRE Via Acquire Media NewsEdge) Dublin - Research and Markets (http://www.researchandmarkets.com/research/9f62q4/pharmapoint) has announced the addition of the "PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023" report to their offering. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. As in the other seven countries covered in this report, Herceptin is the market leader in France, since it was the first HER2-targeting agent to market. Newly-approved drugs tend to gain market access faster in Germany than in the other four EU countries, and this is reflected in the use of Perjeta and Kadcyla in the German HER2-positive breast cancer market. In 2013, Herceptin was the market leader, accounting for 94% of sales in the Italian HER2-positive market. There will be an increase in the breast cancer market size in Spain during the forecast period due to the increased use of HER2-targeted therapies in the neoadjuvant setting, in particular, Perjeta, which is already approved for use in this setting in the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview - Etiology and Pathophysiology - Basic Breast Anatomy - Breast Cancer Staging - Prognosis - Quality of Life - Symptoms 4 Disease Management - France - Germany - Italy - Spain - UK 5 Competitive Assessment Product Profiles - HER2-Targeted Therapies - Herceptin (trastuzumab) - Tykerb (lapatinib) - Perjeta (pertuzumab) - Kadcyla (ado-trastuzumab emtansine, T-DM1) Product Profiles - General Targeted Therapies - Afinitor (everolimus) - Xeloda (capecitabine) - Avastin (bevacizumab) - Halaven (eribulin mesylate) - Abraxane (nab-paclitaxel) Hormonal Agents - Tamoxifen - Faslodex (fulvestrant) - Aromatase Inhibitors 6 Unmet Need and Opportunity - Brain Metastases - Resistance to HER2-Targeting Therapies 7 Pipeline Assessment Promising Drugs in Clinical Development - Gilotrif (afatinib) - Neratinib Promising Drugs in Early-Stage Development - Palbociclib - NeuVax (nelipepimut-S) - Patritumab - Ganetespib - ARRY-380 (ONT-380) - NVP-BYL719 Biosimilars 8 Market Outlook - Global Issues - Forecast - Key Events - Drivers and Barriers 9 Appendix For more information visit http://www.researchandmarkets.com/research/9f62q4/pharmapoint CONTACT: Research and Markets, Laura Wood, Senior Manager. [email protected] Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Breast Cancer (http://www.researchandmarkets.com/categories.asp?cat_id=207&campaign_id=9f62q4) . (c) 2014 M2 COMMUNICATIONS |